Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium
Open accessPublished version of a preprint
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Purpose: The objective of this study was to assess the efficacy and safety of pembrolizumab in combination with standard carboplatin/paclitaxel in patients with advanced endometrial cancer. Patients and Methods: This single-arm, open-label, multicenter phase II study enrolled patients with RECIST measurable advanced endometrial cancer. Patients could have received ≤ 1 prior platinum-based regimen and ≤ one non-platinum chemotherapy. The primary endpoint was objective response rate (ORR). Planned sample size of 46 subjects provided 80% power to detect 15% ORR improvement compared with historical control rate of 50%. Results: A total of 46 patients were enrolled and 43 were evaluable for ORR. Median age was 66 (range: 43–86). Thirty-four (73.9%) patients had recurrent and 12 (26.1%) primary metastatic endometrial cancer. Patients received carboplatin AUC6, paclitaxel 175 mg/m2, and pembrolizumab 200 mg i.v. every 3 weeks for up to six cycles. ORR was 74.4% (32/43), higher than historic controls (P = 0.001). Median progression-free survival (PFS) was 10.6 months (95% confidence interval, 8.3–13.9 months). The most common grade 1–2 treatment-related adverse event (TRAE) included anemia (56.5%), alopecia (47.8%), fatigue (47.8%), and neuropathy (13%), while the most common grade 3–4 TRAEs were lymphopenia, leukopenia, and anemia (19.6% each). High-dimensional spectral flow cytometry (CyTEK) identified enrichment in peripheral CD8+ and CD4+ T-cell populations at baseline in responders. The CD8+ T-cell compartment in responders exhibited greater expression levels of PD-1 and PD-L1 and higher abundance of effector memory CD8+ cells compared with nonresponders. Conclusions: Addition of pembrolizumab to carboplatin and paclitaxel for advanced endometrial cancer was tolerated and improved ORR compared with historical outcomes. Significance: The results of the study support that the combination of pembrolizumab with carboplatin and paclitaxel is well tolerated and active in patients with advanced endometrial cancer. The duration of response and the PFS were significantly longer in patients with mismatch repair deficient/microsatellite instability-high compared with mismatch repair proficient/microsatellite stable tumors. Responders to treatment tend to have enriched CD8+ T-cell and CD4+ T-cell populations among peripheral blood mononuclear cells at baseline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Notably, in patients with advanced endometrial cancer, the addition of pembrolizumab to carboplatin/paclitaxel was found to improve ORR and was well tolerated compared to the placebo/chemotherapy group (ORR: 74.4%; P = 0.001, and mPFS: 10.6 months) [108].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [108]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robinson, M. D., McCarthy, D. J., & Smyth, G. K. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btp616 · Cited by 41,364
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
In silico prediction of protein-protein interactions in human macrophages
Souiai, O., Guerfali, F., Ben Miled, S., Brun, C., & Benkahla, A. (2014) · BMC Research Notes · doi:10.1186/1756-0500-7-157 · Cited by 10,803
Significance analysis of microarrays applied to the ionizing radiation response
Tusher, V. G., Tibshirani, R., & Chu, G. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.091062498 · Cited by 10,568
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Self-citationRahib, L., Smith, B. D., Aizenberg, R., Rosenzweig, A. B., Fleshman, J. M., & Matrisian, L. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-0155 · Cited by 7,094
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 1×
“Pembrolizumab, a mAb that targets the programmed death receptor-1 (PD-1), is approved for treatment of solid tumors that are microsatellite unstable (MSI-H) or mismatch repair deficient (dMMR), independent of tumor site of origin (13, 14).”
BackgroundPD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609 · cited 1×
“During cancer progression, this immune inhibitory pathway is activated when PD-1 ligands (PD-L1 and PD-L2) are upregulated on either tumor or immune cells in the tumor microenvironment (TME) and permits evasion from antitumor immune surveillance (11).”
BackgroundPembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 2×
“Chemotherapy has been shown to be synergistic with immunotherapy in other tumor types (20, 21).”
Background
Cited by
Yusoh, N. A., Ahmad, H., Vallis, K. A., & Gill, M. R. (2025) · Medical Oncology · doi:10.1007/s12032-025-02812-3 · Cited by 40
“Notably, in patients with advanced endometrial cancer, the addition of pembrolizumab to carboplatin/paclitaxel was found to improve ORR and was well tolerated compared to the placebo/chemotherapy group (ORR: 74.4%; P = 0.001, and mPFS: 10.6 months) [108].”
InfluentialFull spectrum flow cytometry in the clinical laboratory
Brestoff, J. R. (2023) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.14098 · Cited by 36
Bian, X., Sun, C., Cheng, J., & Hong, B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15092241 · Cited by 20
Davis, J. M., Rushton, T., Nsiah, F., Stone, R. L., Beavis, A., Gaillard, S. L., Dobi, A., & Fader, A. N. (2024) · Gynecologic Oncology Reports · doi:10.1016/j.gore.2024.101380 · Cited by 10
Kaya, M., Schaddelee, M. P., Creutzberg, C. L., Kroep, J. R., & Horeweg, N. (2025) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2025.101759 · Cited by 9
Metadata
- Authors
- Barber, E. L., Chen, S., Pineda, M. J., Robertson, S. E., Hill, E. K., Teoh, D., Schilder, J., O'Shea, K. L., Kocherginsky, M., Zhang, B., & Matei, D.
- Affiliations
- Northwestern University (US)
- 4Ironwood Cancer and Research Centers, Gilbert, Arizona.
- Indiana University Indianapolis (US)
- University of Iowa Hospitals and Clinics (US)
- University of Minnesota (US)
- 8Department of Preventive Medicine, Northwestern University, Chicago, Illinois.
- Corresponding author
- Zhang, Bin
- Matei, Daniela
- ORCID
- Venue
- Cancer Research Communications
- Published
- 2022-10-28
- Volume
- 2
- Issue
- 10
- Pages
- 1293-1303
- ISSN
- 2767-9764 (ISSN-L)
- PMC
- PMC9648489
- OpenAlex
- W4293010058
- Cited by
- 9
- References
- 52
- Citations by year
- 2025: 4 · 2024: 2 · 2023: 3
- FWCI
- 2.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Cancer Research Communications (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IUScholarWorks (Indiana University) (submittedVersion, cc-by)
- Funders
- HHS | National Institutes of Health (K12 HD050121)
- HHS | NIH | National Cancer Institute (CA208354, CA222963, CA250101)
- Big Ten Research Consortium
- GOG Foundation
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- endometrial adenocarcinoma, pembrolizumab, chemoimmunotherapy, carboplatin, paclitaxel, PD-1 inhibitors, objective response rate, progression-free survival, CD8+ T cells, PD-L1 expression, PD-1, treatment-related adverse events, immunotherapy biomarkers, recurrent endometrial cancer, metastatic endometrial cancer
- MeSH terms
- Adenocarcinoma, Aged, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Female, Humans, Lung Neoplasms, Carboplatin, Endometrial Neoplasms, Paclitaxel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium. https://app.cochat.ai/papers/10.1158/2767-9764.crc-22-0147
- The paper
- Barber, E. L., Chen, S., Pineda, M. J., Robertson, S. E., Hill, E. K., Teoh, D., Schilder, J., O'Shea, K. L., Kocherginsky, M., Zhang, B., & Matei, D. (2022). Clinical and Biological Activity of Chemoimmunotherapy in Advanced Endometrial Adenocarcinoma: A Phase II Trial of the Big Ten Cancer Research Consortium. Cancer Research Communications. https://doi.org/10.1158/2767-9764.crc-22-0147
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.